|
US 11,839,643 B2 |
|
Immunotherapy against several tumors including gastrointestinal and gastric cancer |
Jens Fritsche, Dusslingen (DE); Toni Weinschenk, Aichwald (DE); Steffen Walter, Reutlingen (DE); Peter Lewandrowski, Tuebingen-Hirschau (DE); and Harpreet Singh, Munich (DE) |
Assigned to Immatics Biotechnologies GmbH, Tuebingen (DE) |
Filed by Immatics Biotechnologies GmbH, Tuebingen (DE) |
Filed on May 21, 2021, as Appl. No. 17/327,116. |
Application 14/615,539 is a division of application No. 13/051,665, filed on Mar. 18, 2011, granted, now 9,101,585, issued on Aug. 11, 2015. |
Application 17/327,116 is a continuation of application No. 17/238,943, filed on Apr. 23, 2021. |
Application 17/238,943 is a continuation of application No. 17/161,253, filed on Jan. 28, 2021, granted, now 11,077,171. |
Application 17/161,253 is a continuation of application No. 16/894,212, filed on Jun. 5, 2020, granted, now 10,933,118, issued on Mar. 2, 2021. |
Application 16/894,212 is a continuation of application No. 16/714,098, filed on Dec. 13, 2019, granted, now 10,905,741, issued on Feb. 2, 2021. |
Application 16/714,098 is a continuation of application No. 15/636,486, filed on Jun. 28, 2017, abandoned. |
Application 15/636,486 is a continuation of application No. 14/615,539, filed on Feb. 6, 2015, granted, now 9,717,774, issued on Aug. 1, 2017. |
Claims priority of provisional application 61/315,704, filed on Mar. 19, 2010. |
Claims priority of application No. 1004551 (GB), filed on Mar. 19, 2010. |
Prior Publication US 2021/0275634 A1, Sep. 9, 2021 |
This patent is subject to a terminal disclaimer. |
Int. Cl. A61P 35/00 (2006.01); C07K 7/06 (2006.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); G01N 33/50 (2006.01) |